MPO Antibodies in ANCA-Associated Vasculitis

Diagnostic Significance

The presence of MPO antibodies is a diagnostic marker for ANCA-associated vasculitis, particularly microscopic polyangiitis, and can help identify patients at risk for life-threatening glomerulonephritis and pulmonary hemorrhage, according to the American College of Rheumatology 1, 2, 3
MPO-ANCA positivity establishes the diagnosis of small-vessel vasculitis when combined with compatible clinical features, allowing for immediate initiation of immunosuppressive therapy, as recommended by the European Renal Association 3

MPO antibodies are detected in 35-40% of patients with microscopic polyangiitis (MPA), making it the most common ANCA-associated vasculitis linked to MPO positivity, as reported by the American College of Rheumatology 2, 5
MPO antibodies are present in 35% of eosinophilic granulomatosis with polyangiitis (EGPA) patients, typically those with more renal involvement, according to the European Respiratory Society 5
Approximately 5-10% of granulomatosis with polyangiitis (GPA) cases show MPO-ANCA rather than the typical PR3-ANCA, as noted by the American College of Rheumatology 6
MPO antibodies are detected in pauci-immune necrotizing crescentic glomerulonephritis in 20-40% of cases, as reported by the International Society of Nephrology 5

MPO-ANCA positivity predicts a specific clinical pattern, including rapidly progressive glomerulonephritis with microscopic hematuria, dysmorphic red blood cells, red cell casts, and moderate proteinuria, as described by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 3, 4, 6
MPO-ANCA positivity is also associated with pulmonary-renal syndrome with alveolar hemorrhage in 10% of cases, significantly increasing mortality risk, according to the American Thoracic Society 4
Peripheral neuropathy and mononeuritis multiplex are also common manifestations of MPO-ANCA-associated vasculitis, as reported by the European Neurological Society 4
Palpable purpura indicating dermal small-vessel vasculitis is another common feature of MPO-ANCA-associated vasculitis, as noted by the American Academy of Dermatology 4

MPO-ANCA patients have significantly lower relapse rates compared to PR3-ANCA patients, which fundamentally alters maintenance therapy decisions, according to the European Renal Association 1, 7
In MPO-AAV patients on dialysis without extrarenal manifestations, the relapse risk is so low that maintenance immunosuppression risks may outweigh benefits, as reported by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 1, 7
MPO-AAV patients achieving complete clinical remission with abnormal kidney function may be managed with close monitoring and regular ANCA serologies rather than maintenance immunosuppression, according to the American Society of Nephrology 1, 7

When MPO antibodies are suspected, antigen-specific immunoassays (ELISA) for both MPO-ANCA and PR3-ANCA should be ordered immediately, as recommended by the American College of Rheumatology 3, 4, 6
Urinalysis with microscopy looking for dysmorphic RBCs, RBC casts, and quantify proteinuria should also be performed, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 4
Assessment of renal function using GFR estimating equations is also essential, as reported by the National Kidney Foundation 4
Consider tissue biopsy (kidney has 91.5% diagnostic yield in GPA) for definitive diagnosis, as recommended by the European Renal Association 3, 4